Brokers Set Expectations for Exact Sciences FY2026 Earnings

Exact Sciences Co. (NASDAQ:EXAS) – Analysts at Leerink Partnrs boosted their FY2026 EPS estimates for Exact Sciences in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn $0.81 per share for the year, up from their prior estimate of $0.80. The consensus estimate for Exact Sciences’ current full-year earnings is ($1.10) per share.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The business had revenue of $708.66 million during the quarter, compared to analysts’ expectations of $716.80 million. The company’s quarterly revenue was up 12.8% on a year-over-year basis.

EXAS has been the subject of several other reports. Jefferies Financial Group upped their price objective on shares of Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. TD Cowen raised their price objective on shares of Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Raymond James reaffirmed a “market perform” rating on shares of Exact Sciences in a research report on Thursday, September 26th. BTIG Research increased their target price on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Finally, Benchmark restated a “buy” rating and set a $65.00 price target on shares of Exact Sciences in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $72.94.

Exact Sciences Trading Up 4.9 %

Shares of EXAS stock opened at $54.26 on Wednesday. The stock has a fifty day moving average of $57.24 and a 200 day moving average of $59.38. Exact Sciences has a 52 week low of $40.62 and a 52 week high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy bought 19,500 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were acquired at an average cost of $51.35 per share, for a total transaction of $1,001,325.00. Following the purchase, the chief executive officer now owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. This trade represents a 1.85 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.36% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of EXAS. Chicago Partners Investment Group LLC boosted its holdings in Exact Sciences by 1.7% in the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock worth $651,000 after purchasing an additional 158 shares during the last quarter. Amalgamated Bank boosted its stake in shares of Exact Sciences by 2.7% in the 2nd quarter. Amalgamated Bank now owns 10,937 shares of the medical research company’s stock worth $462,000 after buying an additional 284 shares during the last quarter. Huntington National Bank grew its holdings in shares of Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after acquiring an additional 352 shares during the period. CIBC Asset Management Inc increased its position in Exact Sciences by 6.1% during the third quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock valued at $442,000 after acquiring an additional 371 shares during the last quarter. Finally, Advisors Asset Management Inc. lifted its holdings in Exact Sciences by 1.4% in the third quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company’s stock valued at $1,952,000 after acquiring an additional 402 shares during the period. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.